New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular disease TORONTO , Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020 , Health Canada approved Trulicity® (dulaglutide) to
Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer The Phase 3 monarchE trial evaluating the effects of two years of Verzenio treatment added to
Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for
Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to
- Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo--a 72 percent risk
INDIANAPOLIS , Sept. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.
- FDA Fast Track designation facilitates the development of potential new therapies that treat serious conditions and fulfill an unmet medical need - This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute
- Study Met Primary Endpoint of Reduction of Time to Recovery - Additional Analyses Ongoing to Understand Other Clinical Outcome Data - Lilly's Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib Continues INDIANAPOLIS , Sept.
INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual
INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual fireside